Pharmacologic treatment for detrusor overactivity

H. Henry Lai, Timothy B. Boone, Rodney A. Appell

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Recent pharmacologic treatment for detrusor overactivity has resulted in more favorable side effect profiles, not only because of the use of different drug delivery systems for older drugs but perhaps also due to the improved bladder selectivity of newer antimuscarinic agents. These developments translate into higher patient compliance and better long-term results with the newer agents over generic immediate-release oxybutynin for the treatment of the overactive bladder.

Original languageEnglish
Pages (from-to)365-372
Number of pages8
JournalCurrent urology reports
Issue number5
StatePublished - Sep 2002


  • Detrusor Overactivity
  • Overactive Bladder
  • Oxybutynin
  • Tolterodine
  • Urge Urinary Incontinence


Dive into the research topics of 'Pharmacologic treatment for detrusor overactivity'. Together they form a unique fingerprint.

Cite this